Stay updated with breaking news from Clinical Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
“Our Phase 1a trial has been open 12 months and I’m pleased with both the pace of development and the early responses seen. It’s particularly...
13.12.2021 - NTLA-2002 is the first single-dose genome editing therapeutic candidate designed to prevent angioedema attacks in patients with hereditary angioedema (HAE) to enter clinical studyCAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) - Intellia ... Seite 1
Company to Share Probability Values from its Knee Osteoarthritis (KOA) Study; Analyses Conducted Support Confidence in Initiation of Confirmatory Phase 3...
Part 2 is a Dose Escalation Study of NT219, in Combination with cetuximab (ERBITUX®), in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma...
With the vaccination of children five to 12 years old now underway, two doctors answer questions from New Brunswick parents.